EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 24 / No 11 (Novembre 2008) Med Sci (Paris), 24 11 (2008) 967-971 References
Free Access
Issue
Med Sci (Paris)
Volume 24, Number 11, Novembre 2008
Page(s) 967 - 971
Section M/S revues
DOI https://doi.org/10.1051/medsci/20082411967
Published online 15 November 2008
  1. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89 : 3345–53. [Google Scholar]
  2. Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev 2007; 33 : 542–64. [Google Scholar]
  3. Alibert JL. Nouveaux éléments de thérapeutique et de matière médicale, suivis d’un nouvel essai sur l’art de formuler. Paris, Chez Crapart, Caille et Ravier, 2 vol 1804. [Google Scholar]
  4. Lissauer H. Zwei Faelle von Leucaemie. Berl Klin Wochenschr 1865; 2 : 403–5. [Google Scholar]
  5. Forkner C, McNair-Scott T. Arsenic as a therapeutic agent in chronic myeloid leukemia. JAMA 1931; 97 : 305. [Google Scholar]
  6. Lallemand-Breitenbach V, Zhu J, de Thé H. La leucémie aiguë promyélocytaire : un paradigme ciblés sur l’oncogène ? Med Sci (Paris) 2001; 17: 14–22. [Google Scholar]
  7. Grignani F, Valtieri M, Gabbianelli M, et al. PML/RARa fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000; 96 : 1531–7. [Google Scholar]
  8. De Thé H, Chelbi-Alix MK. APL, a model disease for cancer therapies ? Oncogene 2001; 20 : 7136–9. [Google Scholar]
  9. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72 : 567–72. [Google Scholar]
  10. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339 : 1341–8. [Google Scholar]
  11. Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94 : 2551–6. [Google Scholar]
  12. Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94 : 3978–83. [Google Scholar]
  13. Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor a (RARa) and oncogenic RARa fusion proteins. Proc Natl Acad Sci USA 1999; 96 : 14807–12. [Google Scholar]
  14. Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20 : 7146–53. [Google Scholar]
  15. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268 : 1347–9. [Google Scholar]
  16. Bidère N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24 : 321–52. [Google Scholar]
  17. Rieux-Laucat F. Le syndrome lymphoprolifératif avec auto-immunité : un défaut hérité ou acquis d’apoptose lymphocytaire. Med Sci (Paris) 2006; 22 : 645–50. [Google Scholar]
  18. Renno T, Attinger A, Rimoldi D, et al. Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol 1998; 28 : 540–7. [Google Scholar]
  19. Benihoud K, Bonardelle D, Bobé P, et al. MRL/lpr CD4-CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways. Eur J Immunol 1997; 27 : 415–20. [Google Scholar]
  20. Bobé P, Bonardelle D, Reynès M, et al. Fas-mediated liver damage in MRL hemopoietic chimeras undergoing lpr-mediated graft-versus-host disease. J Immunol 1997; 159 : 4197–204. [Google Scholar]
  21. Bonardelle D, Benihoud K, Kiger N, et al. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice. J Leukoc Biol 2005; 78 : 1052–9. [Google Scholar]
  22. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11 : 294–300. [Google Scholar]
  23. Bonardelle D, Bobé P, Reynès M, et al. Inflammatory arthropathy in MRL hematopoietic chimeras undergoing Fas mediated graft-versus-host syndrome. J Rheumatol 2001; 28 : 956–61. [Google Scholar]
  24. Bobé P, Bonardelle D, Benihoud K, et al. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 2006; 108 : 3967–75. [Google Scholar]
  25. Feldmann M, Maini RN. Anti-TNF-a therapy of rheumatoid arthritis: what have we learned ? Annu Rev Immunol 2001; 19 : 163–96. [Google Scholar]
  26. Durelli L, Ricci A. Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy. Front Biosci 2004; 9 : 2192–204. [Google Scholar]
  27. Parisotto M, Brodeur H, Bhat PV, Mader S. Métabolisme des rétinoïdes et cancer. Med Sci (Paris) 2006; 22 : 1101–6. [Google Scholar]
  28. Bensussan A, Bizzini B, Pouletty P, Gallo RC, Zagury D. Les kinoïdes : Une nouvelle génération de vaccins thérapeutiques. Med Sci (Paris) 2008; 24 : 306–13. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.